In the KEYNOTE 024 phase III trial, pembrolizumab, an anti-programmed death 1 (PD1) antibody, showed better therapeutic effect than standard chemotherapy against EGFR wild type lung cancers overexpressing programmed death-ligand 1 (PD-L1) [5]. Here, EGFR is linked to lung cancer.